0.55
-0.0265(-4.60%)
Currency In USD
| Previous Close | 0.58 |
| Open | 0.56 |
| Day High | 0.57 |
| Day Low | 0.52 |
| 52-Week High | 2 |
| 52-Week Low | 0.31 |
| Volume | 358,828 |
| Average Volume | 798,439 |
| Market Cap | 11.32M |
| PE | -1.2 |
| EPS | -0.46 |
| Moving Average 50 Days | 0.4 |
| Moving Average 200 Days | 0.75 |
| Change | -0.03 |
Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market
GlobeNewswire Inc.
Feb 24, 2026 1:07 PM GMT
150-Patient, Triple-Blinded, Sham-Controlled Study Designed to be Executed in Collaboration with Lindus Health to Support Future FDA Submission for Drug-Free Insomnia Treatment Builds on Prior Peer-Reviewed Clinical Data and International Regulatory
Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders
GlobeNewswire Inc.
Feb 23, 2026 1:18 PM GMT
Multiple new federal actions highlight deep brain neurostimulation as a high-priority emerging therapy for TBI, PTSD, stroke recovery, and Alzheimer’s diseaseHOUSTON, TX, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the
Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer’s, Mood Disorders, TBI & PTSD Care
GlobeNewswire Inc.
Feb 05, 2026 1:37 PM GMT
New digital health platform being launched in partnership with UCSD allows remote physician-monitored neurotherapy subscription models to expand reach, lower cost, and break down treatment stigma for brain-health disordersHOUSTON, TX, Feb. 05, 2026